Standard Chemical & Pharmaceutical Co (1720) Fair Value & Analysis
Healthcare · TW · Market cap 11.2B TWD
Fair value as of: Jun 24, 2026
Analysis
Standard Chemical & Pharmaceutical Co (1720) currently trades at 63.10 TWD, while our model-based Fair Value estimate is 114.21 TWD — implying the stock looks roughly 81.0% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Standard Chemical & Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese and western medicines, cosmetics, beverages, general instruments, and medical devices. It also provides western pharmaceuticals for cardiovascular, metabolic, genitourinary and sex steroids, respiratory, musculoskeletal, digestive, nervous, and circulatory systems; anti-infectives and topical medications; and cancer and cancer antiemetic. In addition, the company offers health food products. Further, it is involved in the manufacture and sale of active pharmaceutical ingredients, as well as veterinary drugs; and sales of medical devices and infant milk powder. It also exports its products. The company was incorporated in 1967 and is headquartered in Tainan City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Standard Chemical & Pharmaceutical Co (1720) undervalued?
What is the fair value of 1720?
What is the quality score of 1720?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.